Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00991419 | To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden | PHASE2 | COMPLETED | 25 | — | — | Feb 1, 2010 | Aug 1, 2011 | Jan 30, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | \[18F\]4694 |
| Name | Type | Description |
|---|---|---|
| [18F]AZD4694 | DRUG | \[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants. |
Inclusion Criteria: * Male or female, of any race or/ethnicity * ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician Exclusion Criteria: * Significant recent (within 6 months) history of neurological (includ...